Drug agency Glenmark Pharmaceuticals on Monday mentioned it has signed an settlement with Canadia’s biotech agency SaNOtize Research and Development Corp to commercialise its Nitric Oxide Nasal Spray for Covid-19 therapy in India and different Asian markets. Glenmark Pharmaceuticals and SaNOtize Research and Development Corp introduced an unique long run strategic partnership to fabricate, market and distribute its breakthrough Nitric Oxide Nasal Spray (NONS) in Asian markets together with India, Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor Leste and Vietnam, Glenmark mentioned in a regulatory submitting.
Glenmark mentioned in early July 2021, the corporate introduced a proposal to the topic professional committee of CDSCO for emergency approval for import and advertising of the nasal spray. “The committee has recommended a phase III clinical trial to be conducted in Indian patients in the weeks to follow. The phase III clinical trial for NONS is expected to be completed, followed by commercial launch under the brand name FabiSpray in India, by fourth quarter of the calendar year 2021,” the corporate added.
This partnership with SaNOtize carefully aligns with Glenmark’s targeted method in opposition to Covid-19 and can assist cut back the burden of the pandemic within the area. mentioned Glenn Saldanha, Chairman and MD, Glenmark Pharmaceuticals. SaNOtize developed and patented a Nitric Oxide Releasing Solution platform know-how (NORSTM) to deal with and stop microbial infections in 2017. Glenmark’s partnership with SaNOtize will herald a lot wanted therapeutic aid to sufferers in India and Asia.
Read all of the Latest News, Breaking News and Coronavirus News right here